Showing results (31-40 of 279) with videos related to
Sort By:
Pageof 28
Cancer Immunology, Immunotherapy : CII|July 6, 2018
Targeting tumor-associated acidity in cancer immunotherapyRuben Lacroix, Elisa A Rozeman, Marina Kreutz, et al.Nature Reviews. Clinical Oncology|May 5, 2023
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanomaMinke W Lucas, Judith M Versluis, Elisa A Rozeman, et al.Cancer Immunology, Immunotherapy : CII|August 18, 2011
Combination of targeted therapy and immunotherapy in melanomaChristian U Blank, Anna I Hooijkaas, John B Haanen, et al.International Archives of Allergy and Immunology|December 12, 2000
Immunologic stimulation of mast cells leads to the reversible exposure of phosphatidylserine in the absence of apoptosisS Martin, I Pombo, P Poncet, et al.Allergy|September 27, 2003
Human serum IgE-mediated mast cell degranulation shows poor correlation to allergen-specific IgE contentF Marchand, S Mecheri, L Guilloux, et al.Cancer Immunology, Immunotherapy : CII|July 4, 2016
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaChristoph Hoeller, Olivier Michielin, Paolo A Ascierto, et al.The Journal of Biological Chemistry|March 6, 1999
Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligandP Launay, C Patry, A Lehuen, et al.International Archives of Allergy and Immunology|January 1, 1993
Expression of the alpha chain of human Fc epsilon RI in transfected rat basophilic leukemia cells: functional activation after sensitization with human mite-specific IgEG Taudou, N Varin-Blank, H Jouin, et al.Molecular Immunology|February 1, 1989
Identification of the Fc gamma RII-related component of murine IgG-BFU Blank, M Daëron, A Galinha, et al.Journal of Cancer Research and Therapeutics|May 5, 2020
Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanomaMarieke A Peters, Marnix H Geukes Foppen, Christian U Blank, et al.Pageof 28